John Gums, Pharm.D., FCCP
Executive Associate Dean And Professor
Department:
Pharmacy Education and Practice
Business Phone:
(352) 273-6308
Business Email:
jgums@ufl.edu
About John Gums
Dr. Gums is the Executive Associate Dean in the University of Florida College of Pharmacy. He also serves as a Professor of Pharmacy and Medicine in the Departments of Pharmacy Education and Practice and Community Health and Family Medicine at UF. Gums received his undergraduate degree in pharmacy from the University of Wisconsin and his Doctor of Pharmacy degree from the Medical University of South Carolina. Subsequently, he completed a fellowship in Family Medicine at the Medical University of South Carolina. Dr. Gums joined the faculty at the University of Florida in 1985, and is actively involved in teaching in the colleges of Pharmacy and Medicine. He has received the Faculty Recognition Award from the College of Pharmacy and twice was selected as Teacher of the Year by the University of Florida, Department of Family Medicine.
Teaching Profile
Courses Taught
2018
MDC7124 Family Med/Geriatrics
2006-2018
PHA5788 Pharmacotherapy 6
2012-2015
PHA5783 Pharmacotherapy 3
2009
PHA5907 Research in Phar Prac
Publications
Academic Articles
2024
Circulating microRNA Biomarkers of Thiazide Response in Hypertension.
Journal of the American Heart Association.
13(4)
[DOI] 10.1161/JAHA.123.032433.
[PMID] 38353215.
2024
Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers.
Clinical and translational science.
17(5)
[DOI] 10.1111/cts.13816.
[PMID] 38747311.
2022
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients
Metabolites.
12(9)
[DOI] 10.3390/metabo12090783.
[PMID] 36144188.
2022
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
The Annals of pharmacotherapy.
56(9):1049-1057
[DOI] 10.1177/10600280211070330.
[PMID] 35040357.
2022
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
Clinical and translational science.
15(12):2858-2867
[DOI] 10.1111/cts.13396.
[PMID] 36271676.
2022
Report of the 2021-2022 Strategic Engagement Standing Committee.
American journal of pharmaceutical education.
86(10)
[DOI] 10.5688/ajpe9448.
[PMID] 36572444.
2021
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites.
11(9)
[DOI] 10.3390/metabo11090645.
[PMID] 34564461.
2021
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.
The American journal of medicine.
134(7):918-925.e2
[DOI] 10.1016/j.amjmed.2020.12.015.
[PMID] 33434556.
2021
The Adaptation of a Clinic-Adjacent Parking Garage for Drive-In COVID-19 Vaccination.
Health services insights.
14
[DOI] 10.1177/11786329211042769.
[PMID] 34526774.
2020
Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic.
Journal of clinical medicine.
9(7)
[DOI] 10.3390/jcm9072274.
[PMID] 32708920.
2020
Ervebo (Ebola Zaire Vaccine, Live/rVSVΔG-ZEBOV-GP): The First Licensed Vaccine for the Prevention of Ebola Virus Disease
Journal of Pharmacy Technology.
36(6):243-250
[DOI] 10.1177/8755122520950692.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology.
9(12):678-685
[DOI] 10.1002/psp4.12563.
[PMID] 33067866.
2020
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
American journal of hypertension.
33(2)
[DOI] 10.1093/ajh/hpz168.
[PMID] 31891170.
2020
Sorting nexin 1 loss results in increased oxidative stress and hypertension.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
34(6):7941-7957
[DOI] 10.1096/fj.201902448R.
[PMID] 32293069.
2019
A stepwise approach to implementing pharmacogenetic testing in the primary care setting.
Pharmacogenomics.
20(15):1103-1112
[DOI] 10.2217/pgs-2019-0053.
[PMID] 31588877.
2019
Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
Therapeutic advances in drug safety.
10
[DOI] 10.1177/2042098619888133.
[PMID] 31807265.
2019
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
131:93-98
[DOI] 10.1016/j.ejps.2019.02.013.
[PMID] 30753892.
2019
Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
The Annals of pharmacotherapy.
53(9):933-939
[DOI] 10.1177/1060028019835166.
[PMID] 30813769.
2019
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-53345-5.
[PMID] 31754133.
2019
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
Clinical and translational science.
12(5):497-504
[DOI] 10.1111/cts.12643.
[PMID] 31033190.
2019
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers.
PloS one.
14(9)
[DOI] 10.1371/journal.pone.0221957.
[PMID] 31532792.
2019
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
American journal of hypertension.
32(7):668-675
[DOI] 10.1093/ajh/hpz022.
[PMID] 30753254.
2019
β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies.
Journal of clinical pharmacology.
59(11):1462-1470
[DOI] 10.1002/jcph.1443.
[PMID] 31090079.
2018
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
The Annals of pharmacotherapy.
52(6):554-561
[DOI] 10.1177/1060028018754383.
[PMID] 29338293.
2018
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
BMC medical genomics.
11(1)
[DOI] 10.1186/s12920-018-0370-x.
[PMID] 29925376.
2018
Evaluation of SAMe-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring.
The Annals of pharmacotherapy.
52(11):1085-1090
[DOI] 10.1177/1060028018779774.
[PMID] 29857777.
2018
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circulation. Genomic and precision medicine.
11(4)
[DOI] 10.1161/CIRCGEN.117.001854.
[PMID] 29650764.
2018
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
Journal of the American Heart Association.
7(6)
[DOI] 10.1161/JAHA.117.007339.
[PMID] 29523524.
2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.
Journal of the American Heart Association.
7(5)
[DOI] 10.1161/JAHA.117.006463.
[PMID] 29478026.
2018
Incident-to Billing for Pharmacists.
Journal of managed care & specialty pharmacy.
24(12):1273-1276
[DOI] 10.18553/jmcp.2018.24.12.1273.
[PMID] 30479200.
2018
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Pharmacogenetics and genomics.
28(11):251-255
[DOI] 10.1097/FPC.0000000000000353.
[PMID] 30289819.
2017
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Journal of clinical hypertension (Greenwich, Conn.).
19(12):1301-1308
[DOI] 10.1111/jch.13094.
[PMID] 28940643.
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Journal of the American Heart Association.
6(11)
[DOI] 10.1161/JAHA.117.006522.
[PMID] 29097388.
2017
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
Circulation. Cardiovascular genetics.
10(1)
[DOI] 10.1161/CIRCGENETICS.116.001404.
[PMID] 28115488.
2017
Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.
Pharmacotherapy.
37(2):236-248
[DOI] 10.1002/phar.1884.
[PMID] 27983747.
2017
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
Journal of the American Heart Association.
7(1)
[DOI] 10.1161/JAHA.117.006656.
[PMID] 29288159.
2017
The benefits of physician-pharmacist collaboration.
The Journal of family practice.
66(12):E1-E8
[PMID] 29202145.
2017
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-16343-z.
[PMID] 29167564.
2016
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Hypertension (Dallas, Tex. : 1979).
68(3):621-9
[DOI] 10.1161/HYPERTENSIONAHA.116.07328.
[PMID] 27381900.
2016
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
American journal of hypertension.
29(10):1186-94
[DOI] 10.1093/ajh/hpw067.
[PMID] 27365079.
2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?
Clinical and translational science.
9(2):114-22
[DOI] 10.1111/cts.12389.
[PMID] 26946962.
2016
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
Metabolomics : Official journal of the Metabolomic Society.
12(8)
[DOI] 10.1007/s11306-016-1076-8.
[PMID] 28217400.
2016
Patient satisfaction with extended-interval warfarin monitoring.
Journal of thrombosis and thrombolysis.
42(4):486-93
[DOI] 10.1007/s11239-016-1385-9.
[PMID] 27251646.
2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.
Hypertension (Dallas, Tex. : 1979).
67(3):556-63
[DOI] 10.1161/HYPERTENSIONAHA.115.06345.
[PMID] 26729753.
2016
Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.
Journal of the American Society of Hypertension : JASH.
10(4):307-17
[DOI] 10.1016/j.jash.2016.01.010.
[PMID] 26852290.
2016
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.
Metabolomics : Official journal of the Metabolomic Society.
12(10)
[DOI] 10.1007/s11306-016-1098-2.
[PMID] 28217401.
2016
The emergence and evolution of antimicrobial resistance: Impact on a global scale.
Bioorganic & medicinal chemistry.
24(24):6440-6445
[DOI] 10.1016/j.bmc.2016.04.027.
[PMID] 27117692.
2015
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication.
PloS one.
10(1)
[DOI] 10.1371/journal.pone.0113808.
[PMID] 25625348.
2015
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
Metabolic syndrome and related disorders.
13(5):195-202
[DOI] 10.1089/met.2014.0132.
[PMID] 25664967.
2015
Correlating the Melatonin (Mt) Pathway With Atenolol Associated Glucose Dysregulation in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
97(1)
2015
Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.
Cardiovascular therapeutics.
33(3):98-103
[DOI] 10.1111/1755-5922.12115.
[PMID] 25786578.
2015
Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
97(1)
2015
Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
97(1):S4-S5
[DOI] 10.1002/cpt.58.
2015
Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
97(1):S4-S5
[DOI] 10.1002/cpt.58.
2015
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Journal of the American Heart Association.
4(1)
[DOI] 10.1161/JAHA.115.001778.
[PMID] 25622599.
2015
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Journal of hypertension.
33(11):2278-85
[DOI] 10.1097/HJH.0000000000000714.
[PMID] 26425837.
2015
Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide.
The pharmacogenomics journal.
15(2):153-7
[DOI] 10.1038/tpj.2014.46.
[PMID] 25201287.
2014
A Novel Simple Method for Determining Cyp2D6 Gene Copy Number and Identifying Allele(S) With Duplication/Multiplication.
Clinical Pharmacology & Therapeutics.
95(1)
2014
Alteration in fasting glucose after prolonged treatment with a thiazide diuretic.
Diabetes research and clinical practice.
104(3):363-9
[DOI] 10.1016/j.diabres.2014.04.004.
[PMID] 24794890.
2014
Baseline predictors of central aortic blood pressure: a PEAR substudy.
Journal of the American Society of Hypertension : JASH.
8(3):152-8
[DOI] 10.1016/j.jash.2013.12.008.
[PMID] 24629400.
2014
Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
Drugs.
74(18):2141-52
[DOI] 10.1007/s40265-014-0325-2.
[PMID] 25414121.
2014
Feasibility of Extended Duration Follow-Up for Patients Receiving Warfarin.
Pharmacotherapy.
34(10)
2014
Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci.
American journal of human genetics.
94(3):349-60
[DOI] 10.1016/j.ajhg.2013.12.016.
[PMID] 24560520.
2014
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.
The pharmacogenomics journal.
14(1):35-40
[DOI] 10.1038/tpj.2013.3.
[PMID] 23400010.
2014
Genome-Wide Association Analysis (Gwas) of Blood Pressure Response To Atenolol-Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
Clinical Pharmacology & Therapeutics.
95(1):S16-S17
2014
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
Journal of internal medicine.
276(5):486-97
[DOI] 10.1111/joim.12215.
[PMID] 24612202.
2014
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Clinical pharmacology and therapeutics.
96(2):175-81
[DOI] 10.1038/clpt.2014.62.
[PMID] 24637943.
2014
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
Circulation. Cardiovascular genetics.
7(2):199-205
[DOI] 10.1161/CIRCGENETICS.113.000421.
[PMID] 24627569.
2014
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.
Journal of the American Heart Association.
3(6)
[DOI] 10.1161/JAHA.114.001398.
[PMID] 25385345.
2014
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
American journal of hypertension.
27(4):546-54
[DOI] 10.1093/ajh/hpt124.
[PMID] 23886594.
2014
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Pharmacotherapy.
34(11):1132-40
[DOI] 10.1002/phar.1483.
[PMID] 25202885.
2014
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Pharmacotherapy.
34(2):123-30
[DOI] 10.1002/phar.1355.
[PMID] 24122840.
2013
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
The pharmacogenomics journal.
13(3):257-63
[DOI] 10.1038/tpj.2012.4.
[PMID] 22350108.
2013
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
The pharmacogenomics journal.
13(5):430-6
[DOI] 10.1038/tpj.2012.34.
[PMID] 22907731.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076984.
[PMID] 24116192.
2013
Changing the direction of clinical pharmacy outside the United States: time to step up.
Pharmacotherapy.
33(2):122-5
[DOI] 10.1002/phar.1247.
[PMID] 23386594.
2013
Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Authors’ reply.
The Annals of pharmacotherapy.
47(3)
[PMID] 23463745.
2013
Fasting Glucose Loci Associated With Glucose Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study
Clinical Pharmacology & Therapeutics.
93
2013
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
62(2):391-7
[DOI] 10.1161/HYPERTENSIONAHA.111.00436.
[PMID] 23753411.
2013
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.
PloS one.
8(1)
[DOI] 10.1371/journal.pone.0052062.
[PMID] 23341889.
2013
Loci influencing blood pressure identified using a cardiovascular gene-centric array.
Human molecular genetics.
22(8):1663-78
[DOI] 10.1093/hmg/dds555.
[PMID] 23303523.
2013
Tracking Thrombosis and Pain Metrics in a Status- Post Orthopedic Surgical Population: Results From a Participating Institution in the Surgical Outcomes Project.
Pharmacotherapy.
33:E227-E228
2012
Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose
Clinical Pharmacology & Therapeutics.
91
2012
Association of Fto With Hydrochlorothiazide (Hctz)-Induced Elevation in Uric Acid (Ua) in African American (Aa) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (Pear) Study.
Clinical Pharmacology & Therapeutics.
91:S59-S60
2012
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
American journal of hypertension.
25(3):359-65
[DOI] 10.1038/ajh.2011.215.
[PMID] 22089105.
2012
Clinical Predictors of Dysglycemic Effects Associated With Use of Beta Blockers and Thiazide Diuretics
Clinical Pharmacology & Therapeutics.
91:S24-S25
2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-56.
[PMID] 22440088.
2012
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Hypertension (Dallas, Tex. : 1979).
60(4):957-64
[DOI] 10.1161/HYPERTENSIONAHA.112.198721.
[PMID] 22949529.
2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Circulation. Cardiovascular genetics.
5(6):686-91
[DOI] 10.1161/CIRCGENETICS.112.964080.
[PMID] 23087401.
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
91
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
91
2012
Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
The Annals of pharmacotherapy.
46(10):1382-91
[DOI] 10.1345/aph.1R069.
[PMID] 23012382.
2012
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
American journal of human genetics.
91(5):823-38
[DOI] 10.1016/j.ajhg.2012.08.032.
[PMID] 23063622.
2012
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-47.
[PMID] 22413836.
2012
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension.
Kidney & blood pressure research.
35(6):477-82
[DOI] 10.1159/000337370.
[PMID] 22688828.
2011
Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
The Annals of pharmacotherapy.
45(5):603-14
[DOI] 10.1345/aph.1P644.
[PMID] 21540406.
2011
Influence of G Protein Receptor Kinase 4 (Grk4) Polymorphisms On Blood Pressure Response To the Beta-Blocker Atenolol.
Clinical Pharmacology & Therapeutics.
89
2011
Kcnj1 Snps Are Associated With Increased Fasting Glucose and Risk of New Onset Diabetes During Hctz Therapy
Clinical Pharmacology & Therapeutics.
89
2011
Place of dabigatran in contemporary pharmacotherapy.
Pharmacotherapy.
31(4):335-7
[DOI] 10.1592/phco.31.4.335.
[PMID] 21449622.
2011
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
Pharmacogenetics and genomics.
21(1):42-9
[DOI] 10.1097/FPC.0b013e328341e911.
[PMID] 21127457.
2010
A Model-Agnostic Framework for Fast Spatial Anomaly Detection
Acm Transactions On Knowledge Discovery From Data.
4(4):1-30
[DOI] 10.1145/1857947.1857952.
2010
Antivirals for influenza: strategies for use in pediatrics.
Paediatric drugs.
12(5):285-99
[DOI] 10.2165/11532530-000000000-00000.
[PMID] 20799758.
2010
Association Between Melatonin Receptor 1B Single Nucleotide Polymorphisms (Snps) and Response To Antihypertensive Drugs.
Clinical Pharmacology & Therapeutics.
87
2010
Combination antihypertensive treatment: is initiation order important?
Journal of clinical hypertension (Greenwich, Conn.).
12(8):565-7
[DOI] 10.1111/j.1751-7176.2010.00319.x.
[PMID] 20695931.
2010
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.
Journal of clinical hypertension (Greenwich, Conn.).
12(1):14-21
[DOI] 10.1111/j.1751-7176.2009.00185.x.
[PMID] 20047624.
2010
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Hypertension (Dallas, Tex. : 1979).
55(1):61-8
[DOI] 10.1161/HYPERTENSIONAHA.109.139592.
[PMID] 19917874.
2010
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
Pharmacogenetics and genomics.
20(8):516-9
[DOI] 10.1097/FPC.0b013e32833b5958.
[PMID] 20555294.
2010
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
American journal of hypertension.
23(9):1014-22
[DOI] 10.1038/ajh.2010.98.
[PMID] 20725057.
2010
You don’t know what you’ve got till it’s gone.
Pharmacotherapy.
30(3):221-3
[DOI] 10.1592/phco.30.3.221.
[PMID] 20180604.
2009
Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.
Expert opinion on drug metabolism & toxicology.
5(7):813-22
[DOI] 10.1517/17425250903044967.
[PMID] 19545214.
2009
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Clinical pharmacology and therapeutics.
86(5):533-9
[DOI] 10.1038/clpt.2009.101.
[PMID] 19571804.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
Pharmacotherapy.
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Pharmacotherapy.
29(10):1157-65
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
American heart journal.
157(3):442-9
[DOI] 10.1016/j.ahj.2008.11.018.
[PMID] 19249413.
2008
Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
The Annals of pharmacotherapy.
42(6):806-16
[DOI] 10.1345/aph.1L016.
[PMID] 18477729.
2008
Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
The Annals of pharmacotherapy.
42(1):71-9
[PMID] 18094350.
2008
Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children.
Expert opinion on pharmacotherapy.
9(2):151-61
[DOI] 10.1517/14656566.9.2.151.
[PMID] 18201141.
2008
Oseltarmivir and Influenza-Related Complications, Hospitalization and Healthcare Expenditure in Healthy Adults and Children
Expert Opinion on Pharmacotherapy.
9:151-161
[DOI] 10.1517/14656566.9.2151.
2007
Antimicrobial resistance in 11 hospitals in Puerto Rico: results of an antimicrobial resistance management (ARM) program.
Puerto Rico health sciences journal.
26(3):181-9
[PMID] 18035809.
2007
Formation of a primary care pharmacist practice-based research network.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
64(19):2044-9
[PMID] 17893415.
2006
Newer agents for the management of overactive bladder.
American family physician.
74(12):2061-8
[PMID] 17186712.
2005
Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
The Annals of pharmacotherapy.
39(3):470-80
[PMID] 15701766.
2005
Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers.
Pharmacotherapy.
25(4):531-9
[PMID] 15977915.
2005
Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
Drugs.
65(14):1949-71
[PMID] 16162020.
2004
Magnesium in cardiovascular and other disorders.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
61(15):1569-76
[PMID] 15372830.
2004
Monitoring pulmonary function in asthma and COPD: point-of-care testing.
The Annals of pharmacotherapy.
38(1):126-33
[PMID] 14742806.
2004
Redefining appropriate use of antibiotics.
American family physician.
69(1):35, 39-40
[PMID] 14727818.
2004
The changing face of antibiotic prescribing: the mutant selection window.
The Annals of pharmacotherapy.
38(10):1675-82
[PMID] 15340128.
2003
NCCLS perspectives in changing susceptibility breakpoints for antimicrobial drugs.
International journal of antimicrobial agents.
22 Suppl 1:S3-13; discussion S25
[PMID] 14512220.
2003
Tezosentan in the treatment of acute heart failure.
The Annals of pharmacotherapy.
37(12):1877-83
[PMID] 14632537.
2002
Assessing the impact of antimicrobial resistance.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
59(8 Suppl 3):S4-6
[PMID] 11977863.
2001
Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins.
The Annals of pharmacotherapy.
35(6):702-6
[PMID] 11408989.
2000
Extended-release nifedipine bezoar identified one year after discontinuation.
The Annals of pharmacotherapy.
34(7-8):862-4
[PMID] 10928396.
1999
A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team.
Pharmacotherapy.
19(12):1369-77
[PMID] 10600085.
1999
Levofloxacin-induced bilateral Achilles tendonitis.
The Annals of pharmacotherapy.
33(7-8):792-5
[PMID] 10466906.
1999
Management of essential hypertension.
Expert opinion on pharmacotherapy.
1(1):71-80
[PMID] 11249566.
1998
Possible lansoprazole-induced eosinophilic syndrome.
The Annals of pharmacotherapy.
32(2):196-200
[PMID] 9496405.
1997
“Isolated” low high-density lipoprotein cholesterol.
The Annals of pharmacotherapy.
31(1):89-97
[PMID] 8997473.
1997
The serum digoxin concentration: ten questions to ask.
American family physician.
56(2):495-503, 509
[PMID] 9262530.
1996
Alpha blockers: a reassessment of their role in therapy.
American family physician.
54(1):263-6, 269
[PMID] 8677841.
1995
Outcome analysis of a pharmacist-managed anticoagulation service.
Pharmacotherapy.
15(6):732-9
[PMID] 8602380.
1995
Recent advances: ambulatory care and family medicine.
The Annals of pharmacotherapy.
29(7-8):716-8
[PMID] 8520089.
1994
Empathy to apathy: a consequence of higher education?
Pharmacotherapy.
14(2):250-1
[PMID] 8197049.
1994
Infectious vaginitis.
Postgraduate medicine.
96(6):85-98
[DOI] 10.1080/00325481.1994.11945924.
[PMID] 29211588.
1994
Infectious vaginitis. Selecting therapy and preventing recurrence.
Postgraduate medicine.
96(6):85-8, 91
[PMID] 7971615.
1994
The Elderly Diabetic Patient With Hypertension: Guidelines for Prescribing Antihypertensive Therapy.
The American journal of geriatric cardiology.
3(5):37-46
[PMID] 11416317.
1993
Carisoprodol as a drug of abuse.
Archives of family medicine.
2(4):429-32
[PMID] 8130923.
1993
Therapeutic drug monitoring in ambulatory care.
The Annals of pharmacotherapy.
27(4):502-5
[PMID] 8477129.
1993
Tuberculosis. The primary care physician’s role in eradication.
Postgraduate medicine.
93(3):46-50, 53
[PMID] 8446526.
1992
Oral antihypertensive agent.
The Journal of family practice.
34(4):397-8
[PMID] 1556531.
1992
Treatment of type I diabetes with a combination of glyburide and insulin.
The Annals of pharmacotherapy.
26(6):757-62
[PMID] 1611155.
1992
Use of ACE inhibitors in the treatment of cardiovascular disease.
American pharmacy.
NS32(6):62-70
[PMID] 1615843.
1991
Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration.
DICP : the annals of pharmacotherapy.
25(7-8):745-6
[PMID] 1949932.
1991
New developments in cardiopulmonary resuscitation.
American family physician.
43(3):832-44
[PMID] 2000728.
1991
Newer antihypertensive agents.
Postgraduate medicine.
89(5):75-81, 84, 89
[PMID] 2008405.
1990
Administration of ACEI test sublingually.
DICP : the annals of pharmacotherapy.
24(11):1116-7
[PMID] 2275241.
1990
Severe verapamil (sustained-release) overdose.
DICP : the annals of pharmacotherapy.
24(7-8):705-6
[PMID] 2375141.
1990
Spironolactone: a re-examination.
DICP : the annals of pharmacotherapy.
24(1):52-9
[PMID] 2405587.
1990
The new antimicrobial agents. When they’re the best choice and when they’re not.
Postgraduate medicine.
88(2):64-8, 71
[PMID] 2199959.
1989
Effects of magnesium oxide on the lipid profile of healthy volunteers.
Atherosclerosis.
77(1):37-42
[PMID] 2719760.
1989
Ventricular arrhythmias. An assessment of newer therapeutic agents.
Postgraduate medicine.
85(6):137-8, 141
[PMID] 2496401.
1988
Comparative evaluation of enalapril and hydrochlorothiazide in elderly patients with mild to moderate hypertension.
Drug intelligence & clinical pharmacy.
22(9):680-4
[PMID] 2850904.
1988
Levothyroxine sodium tablets: chemical equivalence and bioequivalence.
Drug intelligence & clinical pharmacy.
22(7-8):589-91
[PMID] 3046889.
1988
Phenytoin dosing in obese patients: two case reports.
Drug intelligence & clinical pharmacy.
22(9):708-10
[PMID] 3215115.
1988
Ventricular arrhythmias, conclusion: new agents, additional treatment modalities, and overall approach to the problem.
The Journal of the American Board of Family Practice.
1(4):267-73
[PMID] 3066125.
1988
Ventricular arrhythmias, Part I: Prevalence, significance, and indications for treatment.
The Journal of the American Board of Family Practice.
1(2):135-42
[PMID] 2458012.
1988
Ventricular arrhythmias, Part II: Special concerns in evaluation.
The Journal of the American Board of Family Practice.
1(3):201-6
[PMID] 3051894.
1988
Ventricular arrhythmias, Part III: Benefits and risks of antiarrhythmic therapy.
The Journal of the American Board of Family Practice.
1(4):255-66
[PMID] 3066124.
1987
Clinical significance of magnesium: a review.
Drug intelligence & clinical pharmacy.
21(3):240-6
[PMID] 3552543.
1987
Influence of folk medicine on the family practitioner.
Southern medical journal.
80(2):209-12
[PMID] 3810218.
1987
Pharmacokinetic monitoring in the community health-care setting.
Drug intelligence & clinical pharmacy.
21(5):422-6
[PMID] 3582170.
1985
Bilateral knee effusions with cefamandole therapy.
Southern medical journal.
78(10):1268-9
[PMID] 4049055.
1984
Diuretic-induced hypokalemia in uncomplicated systemic hypertension.
The American journal of cardiology.
54(7)
[PMID] 6486051.
in press
Adrenal Gland Disorders
Pharmacotherapy: A Pathophysiologic Approach.
12th ed.(2022)
in press
Cushing Syndrome (book chapter)
Pharmacotherapy Casebook: A Patient Focused Approach.
12th ed.(2023)
Presentations
2022-07-20
Update on Hypertension
State
/
Invited.
Lecture.
Gainesville, Florida
2022-09-14
Update on Anticoagulation
State
/
Invited.
Lecture.
Gainesville, Florida
Grants
Sep 2020
– Sep 2021
COVID-19: Pfizer Drive Thru Vaccine Program
Role: Principal Investigator
Funding: PFIZER INC
Apr 2014
– Mar 2018
MEDication Focused Outpatient Care for Underutilization of secondary prevention
Role: Principal Investigator
Funding: UNIV OF IOWA
via NATL INST OF HLTH NHLBI
Education
Fellowship in Family Medicine
1985
·
Medical University of South Carolina
Pharm.D.
1984
·
Medical University of South Carolina
B.S.
1982
·
University of Wisconsin-Madison
Contact Details
Phones:
- Business:
- (352) 273-6308
Emails:
- Business:
- jgums@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100484
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100484
GAINESVILLE FL 32610